SELECT PUBLICATIONS
André T et al. Phase II study of an optimized 5FU-oxaliplatin strategy (OPTIMOX2)
with celecoxib in metastatic colorectal cancer: A GERCOR study. Proc ASCO
2004;Abstract 3554.
De Gramont A et al. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(Suppl 11):42-5. Abstract
Delaunoit T et al. Chemotherapy permits resection of metastatic colorectal cancer:
Experience from Intergroup N9741. Ann Oncol 2005;16(3):425-9. Abstract
Lenz HJ. Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006;20(5 Suppl 2):5-13. Abstract
Maindrault-Goebel F et al. OPTIMOX-2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2006;Abstract 3504.
Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/rinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancers Symposium 2005;Abstract 169b.
Saltz LB et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO 2005b;Abstract 3508.
Tabernero JM et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc ASCO 2004;Abstract 3512.
Vincenzi B et al. The new era in the treatment of advanced colorectal cancer patients: The role of monoclonal antibodies. Expert Opin Emerg Drugs 2006;11(4):665-83. Abstract
Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5(5):363-7. No abstract available
Wolmark N et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc ASCO
2005;Abstract 3500.
